Lv6
1760 积分 2024-07-01 加入
Mechanism of the glucocorticoid-induced increase in glomerular filtration rate
2小时前
已完结
Inhalable polymer delivers RNA to the lungs
3小时前
已完结
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
24天前
已完结
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
24天前
已完结
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
24天前
已完结
Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease
29天前
已完结
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
1个月前
已完结
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
1个月前
已完结
The Data Monitoring Experience in Empagliflozin Randomized Clinical Trials Between 2011 and 2024
1个月前
已完结
A Tale of Two Diseases
1个月前
已完结
皖公网安备34019202002308
